J. Smeds

发表

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

M. J. van de Vijver, J. Bergh, S. Fox, 2006, Journal of the National Cancer Institute.

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

L. Holmberg, P. Hall, Y. Pawitan, 2005, Breast Cancer Research.

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

P. Hall, Y. Pawitan, J. Bergh, 2005, Proceedings of the National Academy of Sciences of the United States of America.

An expression signature for p 53 status in human breast cancer predicts mutation status , transcriptional effects , and patient survival

P. Hall, Y. Pawitan, J. George, 2005 .

Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.

Joshy George, Yudi Pawitan, Per Hall, 2006, Cancer research.

Low frequency of BRAF and CDKN2A mutations in endometrial cancer

K. Hemminki, Soma Das, I. Jacobs, 2005, International journal of cancer.

Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study

Yudi Pawitan, Chin-Yo Lin, Per Hall, 2006, BMC medicine.

Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: Analysis of loss of heterozygosity

L. Holmberg, J. Bergh, J. Smeds, 2005, Acta oncologica.

Better characterisation of estrogen receptor (ER) positive luminal subtypes using genomic grade

J. Bergh, C. Sotiriou, S. Loi, 2005 .

Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas.

K. Hemminki, J. Smeds, B. Lundh Rozell, 1999, Melanoma research.

Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.

K. Hemminki, Rajiv Kumar, J. Smeds, 2002, Carcinogenesis.

genes are major targets for inactivation

K. Hemminki, Rajiv Kumar, J. Smeds, 2002 .

CORRECTIONS

Y. Pawitan, E. Liu, V. Vega, 1994, The Lancet.

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

Yudi Pawitan, Stefano Calza, Per Hall, 2006, Breast Cancer Research.

Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

K. Hemminki, L. Akslen, Rajiv Kumar, 2002, The American journal of pathology.

A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare

K. Hemminki, L. Akslen, Rajiv Kumar, 2001, International journal of cancer.

Increased frequency of LOH on chromosome 9 in sporadic primary melanomas is associated with increased patient age at diagnosis.

K. Hemminki, J. Smeds, B. Rozell, 2000, Mutagenesis.

Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.

Chin-Yo Lin, Jonas Bergh, Barry Komm, 2006, Cancer research.

Analysis of G1/S checkpoint regulators in metastatic melanoma

K. Hemminki, Rajiv Kumar, J. Smeds, 2000, Genes, chromosomes & cancer.

Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer

J. Bergh, E. Liu, V. Vega, 2007, Breast Cancer Research.

Polymorphic insertion of additional repeat within an area of direct 8 bp tandem repeats in the 5'-untranslated region of the p53R2 gene and cancer risk.

K. Hemminki, J. Smeds, R. Kumar, 2001, Mutagenesis.

Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.

J. Isola, J. Smeds, H. Nordgren, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene profile and response to treatment.

P. Hall, Y. Pawitan, E. Liu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Better characterization of estrogen receptor (ER) positive luminal subtypes of breast cancer using genomic grade.

J. Bergh, C. Sotiriou, S. Loi, 2005 .

Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes

P. Hall, Y. Pawitan, J. Bergh, 2007, Genes, Chromosomes and Cancer.

Abstract P6-12-05: Ways To Understand Mechanism of Action for Targeted Drugs? Gene Expression Analyses from Paired Biopsies in Patients with Advanced Breast Cancer in a Substudy from the Randomized Study Docetaxel +/− Sunitinib A6181064

J. Bergh, J. Smeds, K. Kern, 2010 .

Gene Expression Pro fi ling in Breast Cancer : Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

C. Sotiriou, S. Loi, B. Haibe-Kains, 2006 .

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

M. J. van de Vijver, C. Sotiriou, S. Loi, 2006, Journal of the National Cancer Institute.